DrugPatentWatch Database Preview
Drugs in Development Information for Dactolisib
» See Plans and Pricing
What is the drug development status for Dactolisib?
Dactolisib is an investigational drug.
There have been 4 clinical trials for Dactolisib.
The most recent clinical trial was a Phase 3 trial, which was initiated on October 21st 2019.
The most common disease conditions in clinical trials are Respiratory Tract Infections and [disabled in preview]. The leading clinical trial sponsors are Restorbio Inc., National Institute on Aging (NIA), and [disabled in preview].
There are one hundred and thirty-three US patents protecting this investigational drug and one international patent.
Summary for Dactolisib
| US Patents | 133 |
| International Patents | 1,543 |
| US Patent Applications | 370 |
| WIPO Patent Applications | 2,306 |
| Japanese Patent Applications | 1 |
| Clinical Trial Progress | Phase 3 (2019-10-21) |
| Vendors | 92 |
Recent Clinical Trials for Dactolisib
| Title | Sponsor | Phase |
|---|---|---|
| A Phase 2 Study of RTB101 as COVID-19 Post-Exposure Prophylaxis in Older Adults | National Institute on Aging (NIA) | Phase 2 |
| A Phase 2 Study of RTB101 as COVID-19 Post-Exposure Prophylaxis in Older Adults | Restorbio Inc. | Phase 2 |
| Phase 3 Study to Determine if RTB101 Reduces the Severity of COVID-19 in Older Adults Residing in Nursing Homes | Restorbio Inc. | Phase 3 |
Clinical Trial Summary for Dactolisib
Top disease conditions for Dactolisib
Top clinical trial sponsors for Dactolisib
US Patents for Dactolisib
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Dactolisib | Start Trial | Therapeutic uses of selected pyrrolopyrimidine compounds with anti-mer tyrosine kinase activity | The University of North Carolina at Chapel Hill (Chapel Hill, NC) | Start Trial |
| Dactolisib | Start Trial | Low, immune enhancing, dose mtor inhibitors and uses thereof | Novartis AG (Basel, CH) | Start Trial |
| Dactolisib | Start Trial | Antibody drug conjugates | Novartis AG (Basel, CH) | Start Trial |
| Dactolisib | Start Trial | Triazine compounds as PI3 kinase and mTOR inhibitors | Pfizer Inc. (New York, NY) | Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Dactolisib
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Dactolisib | Australia | AU2015244171 | 2034-04-11 | Start Trial |
| Dactolisib | Australia | AU2015244179 | 2034-04-11 | Start Trial |
| Dactolisib | Canada | CA2945128 | 2034-04-11 | Start Trial |
| Dactolisib | Canada | CA2945129 | 2034-04-11 | Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
